Polycystic Ovarian Syndrome: Is It Time to Rename PCOS to HA-PODS?
- 227 Downloads
The term polycystic ovarian syndrome (PCOS) came into existence 80 years ago. Pathophysiology of PCOS remains ill understood despite extensive research in this field. It is now accepted that the manifestations of PCOS are not confined to the reproductive dysfunction, and there are endocrine–metabolic implications to PCOS with several consequences to female health. PCOS is a misnomer as ovaries do not contain epithelial cysts, but they are actually antral follicles. Moreover, the name PCOS neither reflects the hyperandrogenism which is essential for diagnosis nor the metabolic derangements. While various authors have expressed the need for change of the name, a suitable new option has not yet been established. This review aims to analyse the current understanding of pathophysiology of PCOS and addresses to the controversies associated with its diagnosis and nomenclature. The name “Hyperandrogenic Persistent Ovulatory Dysfunction Syndrome or HA-PODS” is proposed here to overcome diagnostic pitfalls of previous nomenclature. This new name will help formulate appropriate treatment and promote consistency in research as well. Further categorizations of HA-PODS are also discussed in the article.
KeywordsPCOS HA-PODS Renaming PCOS Changing name Misnomer
- 3.Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Wolters Kluwer Health, Lippincot Williams and Wilkins; 2010. p. 83–103.Google Scholar
- 5.National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome (2012). http://prevention.nih.gov/workshops/2012/pcos/docs/PCOS_Final_Statement.pdf. Accessed 31 Jan 2013.
- 8.Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.Google Scholar
- 10.Rojas J, Chávez M, Olivar L, et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med. 2014; 1–17 Article ID 719050, 17 pages. doi:10.1155/2014/719050.
- 27.Krymskaia ML. Sclerocystic ovary syndrome: diagnosis and differential diagnosis. Akush Ginekol (Mosk). 1980;9:53–6.Google Scholar
- 29.National Institutes of Health. Panel recommends changing name of common disorder in women. http://www.nih.gov/news/health/jan2013/od-23.htm. Accessed 31 Jan 2013.
- 37.Ledger WL, Atkin SL, Sathyapalan T. Long-term consequences of polycystic ovary syndrome. Green-top guideline no. 33 RCOG November 2014.Google Scholar